Last reviewed · How we verify
Mydriatic Agent
At a glance
| Generic name | Mydriatic Agent |
|---|---|
| Also known as | Tropicamide drops |
| Sponsor | Eyenuk, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Comparison of 4 Methods of Eye Drops for Pupil Dilation in Diabetic Patients (NA)
- ACCESS 2: AI for pediatriC diabetiC Eye examS Study 2 (NA)
- OPTDR01 Feasibility for Automated Diabetic Retinopathy Detection
- Implementation of Teleophthalmology in Urban Health Systems Study (NA)
- Assessment of Endothelial Glycocalyx in Patients With Primary Open-angle Glaucoma
- AI for the Detection of Retinal Disease and Glaucoma in Patients With Diabetes Mellitus in Primary Care (NA)
- Pediatric Artificial Intelligence for Retinopathy Screening in Children With Type 1 Diabetes (NA)
- Pharmacodynamics of a Fixed Dose Combination of 0.34% Tropicamide and 2.5% Phenylephrine Hydrochloride, Eye Drop, Solution (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mydriatic Agent CI brief — competitive landscape report
- Mydriatic Agent updates RSS · CI watch RSS
- Eyenuk, Inc. portfolio CI